Medicus Pharma Ltd (NASDAQ:MDCX) Receives $23.50 Average PT from Brokerages

Medicus Pharma Ltd (NASDAQ:MDCX) has received a consensus rating of “Moderate Buy” from the five analysts that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $23.50.

MDCX has been the subject of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Medicus Pharma in a research note on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and set a $27.00 price target on shares of Medicus Pharma in a report on Monday, December 15th.

Institutional Trading of Medicus Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDCX. SeaCrest Wealth Management LLC purchased a new position in shares of Medicus Pharma during the second quarter worth $139,000. Guyasuta Investment Advisors Inc. purchased a new stake in Medicus Pharma during the second quarter worth about $230,000. May Hill Capital LLC purchased a new position in shares of Medicus Pharma in the second quarter valued at approximately $107,000. Jane Street Group LLC purchased a new position in shares of Medicus Pharma in the second quarter valued at approximately $41,000. Finally, Osaic Holdings Inc. grew its holdings in shares of Medicus Pharma by 180.0% in the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after purchasing an additional 9,000 shares in the last quarter.

Medicus Pharma Trading Up 0.8%

Medicus Pharma stock opened at $1.34 on Tuesday. The stock has a market cap of $33.65 million, a P/E ratio of -0.62 and a beta of -1.12. The company has a 50-day moving average price of $1.75 and a 200 day moving average price of $2.20. Medicus Pharma has a 12-month low of $1.28 and a 12-month high of $8.94.

Medicus Pharma (NASDAQ:MDCX) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.27). As a group, analysts forecast that Medicus Pharma will post -1.14 EPS for the current year.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.